Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infection
Di Giambenedetto, Simona, et al.
MetadatosMostrar el registro completo del ítem
The spread of the novel‐Coronavirus infection worldwide represents a challenge for physicians. Particularly, no approved therapy has demonstrated to have an impact in treating patients who develop severe respiratory insufficiency so far. The use of humanized anti‐human inteleukine‐6 receptor antibody tocilizumab seems a promising strategy for these patients.